Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

CONCLUSIONS: The SANTORINI real-world data in Austria suggest that a proportion of high and very high-risk patients remain below the guideline-recommended low-density lipoprotein cholesterol goals. Optimising use of oral ezetimibe and bempedoic acid after statins in the lipid-lowering pathway could result in substantially more patients attaining low-density lipoprotein cholesterol goals, likely with additional health benefits.PMID:37286910 | DOI:10.1007/s00508-023-02221-4

Source: Wiener Klinische Wochenschrift - June 7, 2023 Category: General Medicine Authors: Hermann Toplak Aikaterini Bilitou Hannes Alber Johann Auer Martin Clodi Christoph Ebenbichler Evelyn Flie ßer-Görzer Carmen Gelsinger Ursula Hanusch Bernhard Ludvik Thomas Maca Andreas Schober Reinhard Sock Walter S Speidl Thomas M Stulnig Raimund Weitg Source Type: research